An interventional study of INSECT - Protein suplement based on edible insect flour and Control in Aging, Nutrition and Sustainable Diets, sponsored by Universitat Oberta de Catalunya. Completed at 1 site in Spain. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by Universitat Oberta de Catalunya · Not applicable, Interventional, and Prevention
This pilot randomized, double-blind, controlled trial evaluated the effects of a Tenebrio molitor-enriched protein biscuit combined with a structured physical activity program on cardiometabolic health in older adults. Participants aged 65 years and older were assigned to receive either insect-based or control biscuits following supervised exercise sessions for 28 days. Primary outcomes focused on changes in lipid profile, while secondary outcomes included anthropometric measures, body composition, blood pressure, physical function, glucose metabolism, hepatic function and inflammatory biomarkers.
Population aging and increasing environmental pressures on food systems underscore the need for sustainable dietary strategies that support healthy aging. Edible insects, such as Tenebrio molitor, provide high-quality protein with a substantially lower environmental footprint than conventional livestock and may represent a viable alternative protein source for older adults.
This pilot randomized, double-blind, parallel, controlled study was conducted in community-dwelling adults aged 60 years and older recruited from the Barcelona metropolitan area. Participants were randomly assigned to either an insect-based protein supplementation group or a control group. Both groups participated in an identical supervised physical activity program consisting of strength and resistance exercises performed three times per week over a 28-day intervention period.
The insect-based intervention consisted of three cookies per day, providing 35 g of Tenebrio molitor flour. Control cookies were wheat flour-based and matched for palatability and texture. Cookie consumption was supervised by a dietitian immediately after exercise sessions to ensure compliance. Participants were instructed to maintain their habitual diet and lifestyle throughout the study.
Primary outcomes included changes in conventional lipid profile parameters. Secondary outcomes comprised body weight, body composition, blood pressure, muscle strength and physical performance, glucose metabolism, hepatic enzymes, inflammatory biomarkers, advanced lipoprotein profiling, and plasma low-molecular-weight metabolites. Dietary intake was assessed using 3-day food records, and fasting blood samples were collected at baseline and post-intervention.
In addition, acceptability and organoleptic perception of the intervention products were evaluated using structured questionnaires, assessing taste, texture, appearance, and overall satisfaction. Gastrointestinal tolerance, including symptoms such as bloating, discomfort, and changes in bowel habits, was systematically recorded throughout the intervention. Participants' willingness to continue consuming the insect-based product after study completion was also assessed to explore feasibility and long-term adherence.
2,426 studies on the registry are indexed under Motor Activity; 1,161 are open to participants now.
This study's enrollment of 30 is below the median of 60 across 2,118 interventional studies indexed under Motor Activity.
Browse Motor Activity studies →Universitat Oberta de Catalunya is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eligibility Criteria
Inclusion Criteria:
Exclusion Criteria:
Participants consumed three Tenebrio molitor-enriched cookies per day (35 g insect flour/day) immediately after supervised exercise sessions, three times per week for 28 days.
Dietary Supplement: INSECT - Protein suplement based on edible insect flour
Participants consumed three wheat flour-based control cookies per day immediately after supervised exercise sessions, three times per week for 28 days.
Dietary Supplement: Control
Participants received a protein suplement in the form of cookies based on edible insect flour.
Control placebo
Lipid profile
Changes in lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides) and lipid particles (small, medium and large lipoproteins) Description: Changes in the lipid profile were assessed by measuring fasting plasma concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides at baseline and after the intervention. In addition, detailed lipoprotein particle profiling was performed to quantify the concentration and size distribution of lipoproteins, including small, medium, and large subclasses of LDL, HDL, and very-low-density lipoproteins (VLDL). These measures allowed evaluation of both conventional lipid parameters and qualitative changes in lipoprotein particle composition associated with the intervention.
Time frame: One month (baseline and after the intervention)
Body Weight (Kg)
Body weight will be measured in kilograms (kg) using a calibrated digital scale, with participants wearing light clothing and no shoes. The change in body weight will be calculated as the difference between baseline and Day 28 measurements
Time frame: Baseline to 28 days
Change in blood pressure (mmHg) .
Changes in systolic and diastolic blood pressure will be assessed to evaluate the cardiovascular response to the dietary intervention throughout the study period. Blood pressure will be measured in millimeters of mercury (mmHg) at baseline and at Day 28, using a calibrated sphygmomanometer. Changes from baseline to Day 28 will be calculated for both systolic and diastolic values.
Time frame: Baseline to 28 days
Change in Handgrip Strength (kg)
Handgrip strength will be measured in kilograms (kg) using a calibrated handheld dynamometer under standardized conditions. The outcome will be expressed as the maximum value obtained from repeated trials of the dominant hand. The change in handgrip strength will be calculated as the difference between baseline and Day 28 measurements. Higher values indicate greater muscle strength.
Time frame: Baseline to 28 days
Change in glucose (mg/dL).
Changes in fasting blood glucose will be measured in milligrams per deciliter (mg/dL) to determine changes in glycemic control associated with the dietary intervention. Blood glucose concentrations will be measured at baseline and at Day 28, and changes from baseline to Day 28 will be calculated.
Time frame: Baseline to 28 days
Change in hepatic enzymes (ALT, AST, GGT)
Serum hepatic enzymes (ALT, AST, and GGT) will be analyzed as markers of liver function and to explore potential effects of the intervention on hepatic metabolic health.
Time frame: Baseline to 28 days
Change in inflammatory biomarkers
Circulating inflammatory biomarkers will be measured to evaluate changes in systemic inflammation in response to the intervention
Time frame: Baseline to 28 days
Change in plasma low molecular weight metabolite
Plasma low molecular weight metabolites will be analyzed using metabolomic approaches to characterize metabolic changes associated with the intervention.
Time frame: Baseline to 28 days
Change in plasma and red blood cells fatty acids
Fatty acid composition in plasma and red blood cells will be assessed to evaluate changes in lipid metabolism and fatty acid status following the intervention.
Time frame: Baseline to 28 days
Changes in Energy Intake (kcal/day)
Dietary intake will be assessed using 3-day food records collected at baseline and during the last week of the intervention. Mean daily energy intake will be calculated and expressed in kilocalories per day (kcal/day) using EasyDiet software. The change in energy intake will be calculated as the difference between baseline and Day 28 values.
Time frame: Frame: Baseline to 28 days
Changes in Dietary Carbon Footprint (kg CO₂-eq/day)
Dietary carbon footprint (kg CO₂-equivalents/day) will be estimated by linking reported food intake to a validated life cycle assessment database (Poore \& Nemecek (via OWID) and WFLDB - World Food LCA Databas) Changes from baseline to the last week of intervention will be calculated.
Time frame: Baseline to 28 days
Change in Body Mass Index (kg/m²)
Body mass index (BMI) will be calculated as weight in kilograms divided by height in meters squared (kg/m²). Height will be measured at baseline using a calibrated digital scale. Changes in BMI will be calculated as the difference between baseline and Day 28 values.
Time frame: Baseline to Day 28
Change in Body Fat Percentage (%)
Body fat percentage (%) will be assessed using bioelectrical impedance analysis (BIA) under standardized conditions. The change in body fat percentage will be calculated as the difference between baseline and Day 28 measurements.
Time frame: Baseline to Day 28
Change in Lean Mass Percentage (%)
Lean mass percentage (%) will be assessed using bioelectrical impedance analysis (BIA) under standardized conditions. The change in lean mass percentage will be calculated as the difference between baseline and Day 28 measurements.
Time frame: Baseline to Day 28
Change in Vivifrail Physical Performance Battery Total Score (points)
Changes in physical performance will be assessed using the Vivifrail Physical Performance Battery (VPPB), a standardized functional assessment that evaluates lower-limb strength, balance, gait speed, and functional capacity in older adults. The total score ranges from 0 to 12 points, with higher scores indicating better physical performance. The primary outcome will be the change in the total VPPB score, calculated as the difference between baseline and Day 28 measurements. \[Time Frame: Baseline to Day 28\].
Time frame: Baseline to Day 28
Change in Protein Intake (g/day)
Dietary intake will be assessed using 3-day food records collected at baseline and during the last week of the intervention. Mean daily protein intake will be calculated and expressed in grams per day (g/day) using EasyDiet software. The change in protein intake will be calculated as the difference between baseline and Day 28 values.
Time frame: Baseline to Day 28
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitat Oberta de Catalunya